molecules of the month


inhaled dual PI3K_,_ kinase inhibitor

Ph. II (3 mg QD) for asthma; withdrawn

from re-opt. of oral PI3K_ inhibitor

Journal of Medicinal Chemistry

AstraZeneca, Gothenburg, SE

1 min read

7. The AstraZeneca inhaled dual PI3K_,_ inhibitor AZD8154 is long-acting in the lung but has low systemic exposure and is selective, potentially avoiding the known side effects of systemic PI3K inhibition. The molecule is active in cells derived from asthmatic patients as well as in a rat model, and entered Ph. 2 trials (NCT04187508) but was withdrawn due to emerging preclinical toxicology findings.

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: